New dosing strategy aims to keep myeloma patients out of the hospital

NCT ID NCT06421675

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 31 times

Summary

This study tests a new way of giving the drug elranatamab to people with multiple myeloma that has come back or stopped responding to other treatments. The goal is to see if giving the drug in an outpatient setting and on a less frequent schedule can reduce hospital stays and serious infections. About 40 participants will receive elranatamab alone, and researchers will track how safe and tolerable the new dosing plan is.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Juravinski Cancer Center

    RECRUITING

    Hamilton, Ontario, L8V 1C3, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Kingston General Hospital

    RECRUITING

    Kingston, Ontario, K7L 2V7, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • London Health Science Centre - Victoria Hospital

    NOT_YET_RECRUITING

    London, Ontario, N6A 5W9, Canada

  • Ottawa Hospital

    RECRUITING

    Ottawa, Ontario, K1H 8L6, Canada

    Contact Phone: •••-•••-••••

  • Vancouver Cancer Center

    RECRUITING

    Vancouver, British Columbia, V5Z 1L3, Canada

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.